Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03964532 · ClinicalTrials.gov registry record · Phase 1

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

A Phase 1 study of Breast Cancer, sponsored by Georgetown University.

Active
Registry status
Phase 1
Development phase
24
Enrollment target
2
Study locations

NCT03964532 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Georgetown University. The registered enrollment target is 24 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03964532, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Georgetown University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial is designed to assess the safety and tolerability of induction talazoparib followed by combination of talazoparib and avelumab. As an exploratory endpoint, the study team will evaluate the immunomodulatory effects of induction talazoparib followed by the combination of talazoparib and avelumab in patients with advanced breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Talazoparib
  • DRUG Avelumab

Study Locations (2)

District of Columbia

  • MedStar Georgetown University Hospital - Washington D.C.

Utah

  • University of Utah, Huntsman Cancer Institute - Salt Lake City

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2019-04-17
Est. Completion 2026-03
Phase Phase 1

Sponsor

Georgetown University

227 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03964532

The ClinicalTrials.gov registry entry for NCT03964532 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Talazoparib is the first listed.

NCT03964532 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Utah.

Frequently Asked Questions

What is clinical trial NCT03964532 about?

NCT03964532 is a clinical study titled "TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer". This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial is designed to assess the safety and tolerability of induction talazoparib followed by combination of talazoparib and avelumab. As an exploratory endpoint, the study team will evaluate the immunomodulatory ...

What is the current status of trial NCT03964532?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-04-17. Estimated completion is 2026-03.

What conditions does trial NCT03964532 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03964532?

The interventions under investigation include: Talazoparib (DRUG), Avelumab (DRUG).

Who is sponsoring clinical trial NCT03964532?

This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03964532 being conducted?

This trial has 2 study locations across District of Columbia, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.